We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

4 hedge funds and large institutions have $464K invested in ProShares UltraShort NASDAQ Biotechnology in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

8.28% less ownership

Funds ownership: 14.82% → 6.55% (-8.3%)

33% less funds holding

Funds holding: 6 → 4 (-2)

57% less capital invested

Capital invested by funds: $1.08M → $464K (-$615K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$99.5K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$704K
2
TRCT
Tower Research Capital (TRC)
New York
-$24.8K
3
Citigroup
Citigroup
New York
-$1.55K

BIS Hedge Fund Activity: Q1 2025 in Review

4 institutional investors reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2025, worth a combined $464K — down 57% from $1.08M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BIS and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Susquehanna International Group, adding an estimated $99.5K. The largest seller was Jane Street, exiting entirely with an estimated $704K sold.

  • 4 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2025, down from 6 in Q4 2024.
  • Funds reported $464K of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2025, down 57% quarter-over-quarter.
  • 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2025 and 2 closed out, a net change of -2 holders.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2025 was Susquehanna International Group, an estimated $99.5K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2025 was Jane Street, an estimated $704K sold.

Based on aggregated 13F filings for Q1 2025.